4.8.10.2Vertical

Orthopedic Biologics & Regenerative

Bone graft substitutes, PRP, and biologic orthopedic products.

Market snapshot

These figures describe Orthopedic & Spine Devices (4.8.10), the segment that Orthopedic Biologics & Regenerative sits within — not Orthopedic Biologics & Regenerative on its own.

FragmentationConsolidatedEstimate

Within surgical & medical instruments (NAICS 339112); the Census Bureau does not split out orthopedic and spine, so the segment is not separately sized.

Business model & economics

Revenue model

Implant sales plus enabling technology and instruments

Key economics

Recurring revenue
Moderate

procedure-driven implant demand

EBITDA margin
20–30%
Capex intensity
High

Characteristics

  • Aging demographics drive joint-replacement volumes.
  • Shift to ASCs and robotic-assisted procedures.
  • Enabling technology (robotics, navigation) a battleground.

M&A deal context

Deal activityHigh

Who’s acquiring

  • Orthopedic strategics
  • Robotics & enabling-tech acquirers
  • PE- and VC-backed innovators

What’s driving deals

  • Acquisition of robotics and enabling technology.
  • Aging-demographic implant demand.
  • Ambulatory-surgery-center procedure shift.

Find Orthopedic Biologics & Regenerative acquisition targets

Search Acquisera’s index for companies classified under Orthopedic Biologics & Regenerative (4.8.10.2) and build a targeted deal pipeline.

Search companies